Abbott Laboratories (NYSE:ABT) (NYSE: ABT), founded in 1888 by Wallace C. Abbott, is a global healthcare company committed to discovering, developing and manufacturing a wide array of therapeutic and diagnostic products. Headquartered in Abbott Park, Illinois, the company has evolved from its pharmaceutical origins into a diversified provider of medical devices, diagnostics, nutrition and branded generic pharmaceuticals, serving patients and healthcare professionals in more than 160 countries.
The company’s medical devices division offers products designed to improve outcomes in cardiovascular care, neuromodulation and structural heart interventions. Its portfolio includes interventional cardiology tools, implantable cardiac rhythm management systems and neuromodulation therapies. In diagnostics, Abbott provides immunoassay and clinical chemistry platforms, point-of-care instruments, molecular diagnostics and rapid tests that enable accurate and timely clinical decisions across hospital laboratories, physician offices and remote settings.
In the nutrition segment, Abbott delivers science-based infant formulas, pediatric and adult nutritional products that support life-stage health and wellness. These offerings draw on the company’s expertise in vitamins, minerals and specialty nutrients to address global dietary needs. Abbott’s branded generics unit focuses on high-quality, cost-effective therapies in therapeutic areas such as women’s health, cardiovascular disease and metabolic disorders, with an emphasis on expanding access to medicines in emerging markets.
With a strong commitment to research and development, Abbott collaborates with academic institutions, healthcare providers and nonprofit organizations to drive medical innovation and improve patient care. Under the leadership of President and Chief Executive Officer Robert B. Ford, the company continues to uphold rigorous quality and regulatory standards while advancing its mission to enhance lives through pioneering healthcare solutions.
